Zobrazeno 1 - 10
of 65
pro vyhledávání: ''
Publikováno v:
Anti-Cancer Drugs. 32:210-214
Treatment options for unresectable local recurrence or metastatic well-differentiated/dedifferentiated liposarcoma (WDLS/DDLS) remain limited. Different liposarcoma subtypes have varying clinical features and sensitivities to treatment regimens. The
Autor:
Kazuhiko Nakagawa, Seiichiro Mitani, Shinichiro Suzuki, Takashi Kurosaki, Yasumasa Nishimura, Hidetoshi Hayashi, Soichi Fumita, Naoki Otsuki, Kazuki Ishikawa, Takeshi Yoshida, Katsumi Doi, Hiroaki Kanemura, Koji Haratani, Kaoru Tanaka, Mutsukazu Kitano, Tsutomu Iwasa
Publikováno v:
Anti-Cancer Drugs
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety a
Publikováno v:
Anti-Cancer Drugs. 31:973-978
Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either protein expression using immunohistochemistry (IHC) or gene amplification using fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive breast can
Publikováno v:
Anti-cancer drugs. 33(1)
Arrhythmias associated with antibody-drug conjugates (ADCs) are rare but potentially life-threatening adverse events (AEs). No study has systemically compared arrhythmias associations for various marketed ADCs. This needs to be clarified to guide ant
Publikováno v:
Anti-cancer drugs. 33(1)
Triple-negative breast cancer (TNBC) has a very high rate of recurrence. Our aim is to investigate the efficacy of bevacizumab, platinum and paclitaxel as first-line in metastatic TNBC (mTNBC). This study included 54 female patients with mTNBC. They
Publikováno v:
Anti-cancer drugs. 31(7)
Treatment with abiraterone acetate or enzalutamide is one of the approved approaches in men with metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting. However, a significant fraction of patients do not respond to trea
Autor:
Hiroki Matsui, Hideo Yasunaga, Hirokazu Urushiyama, Wakae Hasegawa, Kiyohide Fushimi, Yasuhiro Yamauchi, Yukiyo Sakamoto, Akihisa Mitani, Taisuke Jo, Takahide Nagase
Publikováno v:
Anti-Cancer Drugs. 29:560-564
An association between chemotherapy and venous thromboembolic events (VTEs) in patients with cancer is well established, with cisplatin (CDDP) being one of the most well-studied risk factors. However, whether CDDP is more strongly associated with occ
Autor:
Christine Bryla, Christophe E. Redon, Yusuke Tomita, William M. Bonner, Susan E. Bates, Giuseppe Giaccone, Arun Rajan, Tito Fojo, Min-Jung Lee, Jane B. Trepel, Sanjeeve Balasubramaniam, Richard Piekarz, William D. Figg, Cody J. Peer
Publikováno v:
Anti-Cancer Drugs. 29:457-465
The standard-of-care for advanced small cell lung cancer (SCLC) is chemotherapy with cisplatin+etoposide (C+E). Most patients have chemosensitive disease at the outset, but disease frequently relapses and limits survival. Efforts to improve therapeut
Publikováno v:
Anti-Cancer Drugs. 27:804-808
Metastatic squamous cell carcinoma (SCCA) anal cancer is relatively rare. With limited data, cisplatin plus 5-fluorouracil has traditionally been utilized in the first-line setting. Treatment beyond front-line cisplatin progression is not well define
Autor:
Daniel Herr, Christoph Mundhenke, Sherko Kümmel, Petra Krabisch, Nicolai Maass, Serban-Dan Costa, Valentina Nekljudova, Kristina Lübbe, Volkmar Müller, Gunter von Minckwitz, Sabine Seiler, Marcus Schmidt, Frederik Marmé, Claudia Schumacher, Bernd Gerber, Sibylle Loibl, Jana Barinoff, Dirk Bauerschlag, Joachim Bischoff, Marc Thill, Eva-Maria Grischke
Publikováno v:
Anti-cancer drugs. 30(4)
The E-VITA study evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer. This multicenter, open-label phase II trial, randomly assigned patien